U.S. ’super bugs’ invading several Colombian cities



While the physiological damage and social havoc created by alcohol abuse and dependency are well-known, it is also true that light-to-moderate drinking has certain health benefits. This mini-review summarizes a roundtable discussion held at the July 2007 annual meeting of the Research Society on Alcoholism in Chicago, Illinois. Results will be published in the February

Full Post: Light drinking has certain health benefits, researchers look at why

Two clones of highly antibiotic-resistant organism strains, which previously had only been identified in the United States, are now causing serious sickness and death in several Colombian cities including the capital Bogota, say researchers at The University of Texas Medical School at Houston.

The study, done in collaboration with Universidad El Bosque in Bogotá, is presented in a research letter published in the Nov. 13 issue of the New England Journal of Medicine.

U.S. clones of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VREF) have emerged in communities across Colombia. The variation of the MRSA clone, referred to as the USA 300, has been previously reported to be the most important cause of severe skin and soft tissue infections in the United States. The VREF clone is genetically related to a strain that hit a Houston hospital in 1994.

In Colombia before 2005, there were no recorded cases of any community-associated MRSA infections, including USA 300 MRSA. In 2005, there were two: one in Bogotá and one in the city of Villavicencio. Now the number of MRSA infections is climbing across the country. The paper reports a total of 15 infections, some of which were documented in two additional cities between 2006 and 2007, said Cesar A. Arias, M.D., Ph.D., assistant professor of infectious diseases at the UT Medical School at Houston.

The first case of VREF was reported in Bogotá in 2001. Since then, 50 additional cases have been identified at seven hospitals.

“We are tracking and recording these cases to find the link between the U.S. and Colombia. The goal is to find out why and how these organisms got there. With this information, researchers hope to better understand the molecular epidemiology of these super bugs to understand how they spread and how to control them,” Arias said. “The UT Medical School will continue to work with Latin American academic institutions to learn more about these antibiotic-resistant organisms.”

All patients diagnosed with community-associated MRSA infections suffered severe skin and soft-tissue infections. Some patients also experienced death of tissue surrounding bones, bacteria in the bloodstream and meningitis, and 20 percent of the patients died. The MRSA infections were treatable with common antistaphylococcal antibiotics, although 40 percent were resistant to tetracycline.

Arias added that the USA 300 clone of MRSA has not only been found in Colombia. In a recent presentation at the annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America in Washington, D.C., Arias shared the news that this clone has been recorded in multiple patients in Ecuador and Venezuela.

http://www.uthouston.edu/

Link




Rates of antibiotic-resistant head and neck infections increased in pediatric patients nationwide between 2001 and 2006, according to a report in the January issue of Archives of Otolaryngology-Head & Neck Surgery. Before the 1980s, infections with strains of the bacteria Staphylococcus aureus resistant to the antibiotic methicillin (methicillin-resistant Staphylococcus aureus, or MRSA) were most often

Full Post: MRSA head and neck infections increase among children



Pre-operative screening of patients for methicillin-resistant Staphylococcus aureus (MRSA) may be an effective way to reduce infection rates following otolaryngic surgeries, according to new research published in the January 2009 issue of Otolaryngology - Head and Neck Surgery. The study, conducted by researchers at the Massachusetts Ear & Eye Infirmary, is the first to review otolaryngic

Full Post: MRSA pre-screening effective in reducing otolaryngic surgical infection rates



Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), has announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. The FDA has indicated that they cannot approve

Full Post: FDA issues complete response letter for Ceftobiprole for treatment of complicated skin infections



Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone. Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name Zevtera.

Full Post: Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections



Targanta Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. AIDAC will review Targanta’s New Drug Application (NDA) for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive

Full Post: Targanta Therapeutics announces posting of briefing documents for review of FDA